Physician profile
James Tran
NPI 1477665966
$1,810.03
in general payments reported to CMS, 2019-2025
17 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $50.67 · 2021: $39.26 · 2022: $295 · 2023: $264 · 2024: $415 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $990.98 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $311.45 | 2019-2021 | |
| Alcon Vision LLC | $132.14 | 2024 | Dailies Total1 |
| Abbvie INC. | $63.48 | 2022-2024 | Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.59 | 2019-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $57.73 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Hikma Pharmaceuticals USA | $43.28 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $31.22 | 2022 | |
| Boston Scientific Corporation | $24.60 | 2023 | |
| Atricure, INC. | $21.00 | 2024 | |
| Nestle Healthcare Nutrition INC. | $18.20 | 2022 | |
| Novo Nordisk INC | $15.53 | 2019 | |
| Ucb, INC. | $14.47 | 2019 | |
| Althera Pharmaceuticals LLC | $14.43 | 2021 | |
| Pfizer INC. | $12.93 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.